HomeCompareHGHAF vs ABBV

HGHAF vs ABBV: Dividend Comparison 2026

HGHAF yields 340.32% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HGHAF wins by $4930008583629521920.00M in total portfolio value
10 years
HGHAF
HGHAF
● Live price
340.32%
Share price
$0.66
Annual div
$2.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4930008583629521920.00M
Annual income
$4,927,227,230,983,960,000,000,000.00
Full HGHAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HGHAF vs ABBV

📍 HGHAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHGHAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HGHAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HGHAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HGHAF
Annual income on $10K today (after 15% tax)
$28,926.99/yr
After 10yr DRIP, annual income (after tax)
$4,188,143,146,336,366,300,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HGHAF beats the other by $4,188,143,146,336,366,300,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HGHAF + ABBV for your $10,000?

HGHAF: 50%ABBV: 50%
100% ABBV50/50100% HGHAF
Portfolio after 10yr
$2465004291814760960.00M
Annual income
$2,463,613,615,491,980,000,000,000.00/yr
Blended yield
99.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HGHAF
No analyst data
Altman Z
-4.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HGHAF buys
0
ABBV buys
0
No recent congressional trades found for HGHAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHGHAFABBV
Forward yield340.32%3.06%
Annual dividend / share$2.23$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$4930008583629521920.00M$102.3K
Annual income after 10y$4,927,227,230,983,960,000,000,000.00$24,771.77
Total dividends collected$4929826446411726848.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HGHAF vs ABBV ($10,000, DRIP)

YearHGHAF PortfolioHGHAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$78,764$68,063.51$11,550$430.00+$67.2KHGHAF
2$1,086,318$1,002,041.34$13,472$627.96+$1.07MHGHAF
3$26,994,708$25,832,347.91$15,906$926.08+$26.98MHGHAF
4$1,228,747,298$1,199,862,959.86$19,071$1,382.55+$1228.73MHGHAF
5$103,399,728,003$102,084,968,394.33$23,302$2,095.81+$103399.70MHGHAF
6$16,167,653,599,323$16,057,015,890,359.24$29,150$3,237.93+$16167653.57MHGHAF
7$4,710,170,801,577,979$4,692,871,412,226,704.00$37,536$5,121.41+$4710170801.54MHGHAF
8$2,560,531,923,845,360,000$2,555,492,041,087,672,000.00$50,079$8,338.38+$2560531923845.31MHGHAF
9$2,599,394,995,852,275,000,000$2,596,655,226,693,760,300,000.00$69,753$14,065.80+$2599394995852275.00MHGHAF
10$4,930,008,583,629,522,000,000,000$4,927,227,230,983,960,000,000,000.00$102,337$24,771.77+$4930008583629521920.00MHGHAF

HGHAF vs ABBV: Complete Analysis 2026

HGHAFStock

High Arctic Energy Services Inc., an oilfield services company, provides oilfield services to exploration and production companies in Canada and Papua New Guinea. The company operates through three segments: Drilling Services, Production Services, and Ancillary Services. It offers snubbing services, including foothills standalone snubbing system for completions and workovers; hydraulic workover units, such as a patented L-Frame equipment configuration; rig assist snubbing unit, a truck-mounted hydraulic system to manage underbalanced wellbore conditions; and power tower to install a snubbing unit and blowout preventers in one lift. The company also rents oilfield equipment comprising accumulators, blowout preventers, casing cutters and scrappers, hydraulic catwalks, rig shacks, chokes, boilers, boiler blowdown tanks, generators, light towers, cross over and rotary subs, elevators, EUE collars, fire suppression kits, fuel tank skids, hot tap kits, mud cans, pickers, pipe racks, power swivels, pumps, slips, spools, flanges, thread washers, tongs, trailers and accommodations, tubing, gate, plug, hydraulic/air actuated, and safety valves; and kelly cocks for drilling, completions, workover, and abandonment of oil and gas operations. In addition, it provides nitrogen pumping units; and well servicing. Further, the company owns and operates two heli-portable drilling rigs in Papua New Guinea; and offers support equipment, such as rig matting, crawler cranes, water pumps, forklifts/wheel loaders, telehandlers, lighting towers, camps, trucks, wash-down packages, vehicles, and drill pipes and BHA. High Arctic Energy Services Inc. was founded in 1993 and is headquartered in Calgary, Canada.

Full HGHAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HGHAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HGHAF vs SCHDHGHAF vs JEPIHGHAF vs OHGHAF vs KOHGHAF vs MAINHGHAF vs JNJHGHAF vs MRKHGHAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.